[go: up one dir, main page]

ZA943494B - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
ZA943494B
ZA943494B ZA943494A ZA943494A ZA943494B ZA 943494 B ZA943494 B ZA 943494B ZA 943494 A ZA943494 A ZA 943494A ZA 943494 A ZA943494 A ZA 943494A ZA 943494 B ZA943494 B ZA 943494B
Authority
ZA
South Africa
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Application number
ZA943494A
Inventor
Peter Clive Cherry
John Derek Cocker
Andrew David Searle
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA943494B publication Critical patent/ZA943494B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
ZA943494A 1993-05-21 1994-05-02 Chemical compounds ZA943494B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939310635A GB9310635D0 (en) 1993-05-21 1993-05-21 Chemical compounds

Publications (1)

Publication Number Publication Date
ZA943494B true ZA943494B (en) 1995-01-23

Family

ID=10736007

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA943494A ZA943494B (en) 1993-05-21 1994-05-02 Chemical compounds

Country Status (19)

Country Link
EP (1) EP0699196A1 (en)
JP (1) JPH08510455A (en)
CN (1) CN1126473A (en)
AU (1) AU6928794A (en)
BG (1) BG100154A (en)
CA (1) CA2162921A1 (en)
CZ (1) CZ305195A3 (en)
FI (1) FI955587A0 (en)
GB (1) GB9310635D0 (en)
HU (1) HUT73790A (en)
IL (1) IL109703A0 (en)
NO (1) NO954681L (en)
OA (1) OA10195A (en)
PE (1) PE31195A1 (en)
PL (1) PL311702A1 (en)
SK (1) SK142495A3 (en)
TW (1) TW279866B (en)
WO (1) WO1994027989A1 (en)
ZA (1) ZA943494B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2170874A1 (en) * 1993-09-30 1995-04-06 Minoru Okada Azole derivative and pharmaceutical composition thereof
AU3846395A (en) * 1994-11-07 1996-05-31 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
AU702406B2 (en) * 1995-03-01 1999-02-18 Yamanouchi Pharmaceutical Co., Ltd. Imidazole derivatives and medicinal composition thereof
US6420375B1 (en) * 1997-02-21 2002-07-16 Takeda Chemical Industries, Ltd. Fused ring compounds, process for producing the same and use thereof
EP1681290B9 (en) 2000-11-17 2013-06-19 Takeda Pharmaceutical Company Limited Imidazole derivatives, production method thereof and use thereof
US6960586B2 (en) 2000-11-20 2005-11-01 Takeda Pharmaceutical Company Limited Imidazole derivatives, process for their preparation and their use
EP1348706B1 (en) 2000-12-08 2009-08-19 Takeda Pharmaceutical Company Limited Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
EP1902026B1 (en) * 2005-06-24 2010-02-17 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm)
US8093279B2 (en) 2005-12-13 2012-01-10 Gillian Reed, legal representative Compound
GB0525323D0 (en) * 2005-12-13 2006-01-18 Sterix Ltd Compound
CN100586932C (en) * 2007-01-26 2010-02-03 中国医学科学院医药生物技术研究所 Antitumor compound and its preparation method
SI2445903T1 (en) 2009-06-26 2014-07-31 Novartis Ag 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
JP5964756B2 (en) 2010-02-04 2016-08-03 ラジウス ヘルス,インコーポレイテッド Selective androgen receptor modulator
EP3106159A1 (en) 2010-05-12 2016-12-21 Radius Health, Inc. Therapeutic regimens
MX345788B (en) 2010-08-04 2017-02-15 Pellficure Pharmaceuticals Inc * Combination therapy for the treatment of prostate carcinoma.
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
BR112013007685B1 (en) 2010-09-28 2021-11-09 Radius Pharmaceuticals, Inc SELECTIVE ANDROGEN RECEPTOR MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING SUCH COMPOUNDS, METHOD OF IDENTIFYING A COMPOUND CAPABLE OF MODULARING AN ANDROGEN RECEPTOR, USES OF A COMPOUND OR COMPOSITION AND PROCESS FOR PREPARATION OF A COMPOUND
EP2702052B1 (en) 2011-04-28 2017-10-18 Novartis AG 17alpha-hydroxylase/c17,20-lyase inhibitors
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
WO2014158875A1 (en) 2013-03-14 2014-10-02 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
ES2939940T3 (en) 2014-03-28 2023-04-28 Univ Duke Treatment of breast cancer using selective estrogen receptor modulators
CA2960750A1 (en) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
WO2018080933A1 (en) 2016-10-24 2018-05-03 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
IL292245B1 (en) 2017-01-05 2024-12-01 Radius Pharmaceuticals Inc Polymorphic forms of RAD1901–2HCL

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS229934B2 (en) * 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds

Also Published As

Publication number Publication date
FI955587A (en) 1995-11-20
SK142495A3 (en) 1996-06-05
JPH08510455A (en) 1996-11-05
HU9503321D0 (en) 1996-01-29
HUT73790A (en) 1996-09-30
NO954681D0 (en) 1995-11-20
FI955587A0 (en) 1995-11-20
OA10195A (en) 1996-12-18
GB9310635D0 (en) 1993-07-07
CA2162921A1 (en) 1994-12-08
AU6928794A (en) 1994-12-20
EP0699196A1 (en) 1996-03-06
BG100154A (en) 1996-07-31
WO1994027989A1 (en) 1994-12-08
CZ305195A3 (en) 1996-06-12
TW279866B (en) 1996-07-01
CN1126473A (en) 1996-07-10
IL109703A0 (en) 1994-08-26
PL311702A1 (en) 1996-03-04
NO954681L (en) 1995-11-20
PE31195A1 (en) 1995-10-18

Similar Documents

Publication Publication Date Title
GB9304618D0 (en) Chemical compounds
GB9311682D0 (en) Chemical compounds
GB9312210D0 (en) Chemical compounds
GB9305468D0 (en) Chemical compounds
PL311702A1 (en) Chemical compounds
GB9305469D0 (en) Chemical compounds
GB2280677B (en) Chemical compounds
GB9308421D0 (en) Chemical compounds
GB9305509D0 (en) Chemical compounds
GB9307749D0 (en) Chemical compounds
GB9305523D0 (en) Chemical compounds
GB9305510D0 (en) Chemical compounds
GB9305459D0 (en) Chemical compounds
GB9305806D0 (en) Chemical compounds
GB9306941D0 (en) Chemical compounds
GB9307398D0 (en) Chemical compounds
GB9310884D0 (en) Chemical compounds
GB9308420D0 (en) Chemical compounds
GB9308419D0 (en) Chemical compounds
GB9307809D0 (en) Chemical compounds
GB9307806D0 (en) Chemical compounds
GB9309718D0 (en) Chemical compounds
GB9309934D0 (en) Chemical compounds
GB9307339D0 (en) Chemical compounds
GB9310560D0 (en) Chemical compounds